Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05014100Phase 2Unknown

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Role: lead

NCT02621333Phase 2Terminated

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Role: collaborator

NCT03406832Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Role: collaborator

NCT03791827Unknown

Multicenter Registry of Pediatric Lupus Nephritis in China

Role: collaborator

NCT03406819Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Role: collaborator

All 5 trials loaded